Our novel approach optimizes and reinvigorates the natural, innate immune pathway to deliver comprehensive anti-tumor responses and reduce the harm of infectious diseases. With every new therapy, we seek to overcome the limitations of current treatments to achieve meaningful responses in patients.
ASD141, is a novel, innate immune checkpoint inhibitor that commands the innate immune system to coordinate a renewed attack on solid tumors. This therapeutic is part of a diverse pipeline focused on impact creation and includes NanoCherub®, our nanocomplex platform technology that is accelerating the creation of injectable and oral therapeutic and prophylactic vaccines.
Our mission is to create immunotherapies and vaccines that deliver extraordinary benefits to patients around the world.
Our research and innovation strategy is focused on discovering and developing transformational therapies that shape the future for cancer treatments and reduce the harm of infectious diseases.
Science is enabling us to break through the limitations of current cancer treatments and create new, potentially curative therapies. While we pursue high-value commercial candidates that allow the company to grow, our attention is firmly fixed on finding cures that enable people to live healthy lives for longer.
“We are breaking through the limitations of current immunotherapies to enable access for more patients than ever before.”
Our lead product, ASD141, is a powerful immunotherapy targeted to optimize the complex interactions between the innate and the adaptive immune system.
ASD141 works by blocking TLT-1, a key regulatory protein that induces the immune suppressive environment in the tumor. Blocking TLT-1 binding to receptor CD11b reinvigorates the innate cells that coordinate an immune response in the tumor microenvironment. Our anti-TLT-1/CD11b approach has infinite potential to be used both as monotherapy and to help improve the safety and efficacy of existing treatments when used in combination.
Our patented NanoCherub® technology underpins our subunit protein and peptide vaccines. Two drugs have shown promise in early stage studies, to prevent COVID-19 and potentially cure hepatitis B (HBV) in a way that has never been possible before.
Partner of choice for novel immunotherapeutics
Ascendo Biotechnology is a strategic partner of choice for novel immunotherapies which exploit the interplay between the innate and adaptive immune response. We are currently seeking partners to accelerate the development and commercialization of our lead oncology drug, ASD141.
If you’re interested in discussing our programmes, please get in touch: